Nintedanib Viatris

Nintedanib Viatris is a medicine used to treat: - adults with idiopathic pulmonary fibrosis (IPF), a disease of unknown cause in which fibrous (scar) tissue forms in the lungs; - adults and children above the age of 6 years with systemic sclerosis-associated interstitial lung disease (ILD), a disease in which the immune system (the body’s natural defences) is overactive, causing development of fibrous tissue and progressive scarring of the lungs; - adults with other chronic (long-term) interstitial lung diseases that are fibrosing (causing production of fibrous tissue) and progressive (getting worse); - children aged 6 to 17 years with clinically significant, progressive fibrosing ILDs. Nintedanib Viatris contains the active substance nintedanib and is a ‘generic medicine’. This means that Nintedanib Viatris contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU. The reference medicine for Nintedanib Viatris is Ofev.